二甲双胍和阿卡波糖治疗2型糖尿病餐后高血糖的疗效观察
|
摘要
目的研讨2型糖尿病(T2DM)患者使用二甲双胍以及阿卡波糖治疗对餐后高血糖的影响。方法选择我院收治于2016年3月至2019年3月的300例T2DM患者做课题研究,并对所选患者进行随机分组,将150例接受二甲双胍单药治疗者纳入A组,将150例接受二甲双胍与阿卡波糖两药治疗者纳入B组,观察比较两组的餐后高血糖控制情况以及相关临床指标改善情况。结果两组治疗前的血糖指标(FPG与2h PG)、HbAlc检测值相比,P>0.05,无统计学意义;治疗后,B组的血糖指标(FPG与2h PG)、HbAlc检测值相比A组均显著下降,P<0.05,有统计学意义。血脂、BMI与胰岛素指标记录显示,A组与B组治疗前数据相比,P>0.05,无统计学意义;治疗后,B组上述数据相比A组均显著改善,P<0.05,有统计学意义。两组用药期间发生腹痛腹胀、恶心等不良反应的总概率相比,P>0.05,无统计学意义。结论二甲双胍以及阿卡波糖两药联合用于T2DM患者的治疗,对控制患者餐后高血糖、降低患者体质量、调节其血脂与胰岛素水平等均有明显的助益,并且两药合用安全可靠,值得推荐。
Objective To investigate the effects of metformin and acarbose on postprandial hyperglycemia in patients with type2 diabetes mellitus(T2 DM). Methods A total of 300 patients with T2 DM who were admitted to our hospital from March 2016 to March 2019 were enrolled in the study. The selected patients were randomized and 150 patients receiving metformin monotherapy were included in group A, 150 patients. Patients who received both metformin and acarbose were included in group B. The postprandial hyperglycemia control and improvement of relevant clinical indicators were compared between the two groups. Results Before the treatment, the blood glucose index(FPG and 2 h PG) and HbAlc detection values were P>0.05, which was not statistically significant.After treatment, the blood glucose index(FPG and 2 h PG) and HbAlc detection value of group B were compared with A. The group was significantly decreased, P<0.05, statistically significant. Blood lipids, BMI and insulin index records showed that P>0.05 compared with the pre-treatment data of group A and group B, no statistical significance; after treatment, the above data of group B were significantly improved compared with group A, P<0.05, there were statistics. Learning meaning. The total probability of abdominal reactions such as abdominal pain, bloating, and nausea during the two groups was P>0.05, which was not statistically significant. Conclusion The combination of metformin and acarbose in the treatment of patients with T2 DM has obvious benefits in controlling postprandial hyperglycemia, reducing the body weight of patients, regulating blood lipids and insulin levels, and the two drugs are safe. Reliable and worth recommending.
Objective To investigate the effects of metformin and acarbose on postprandial hyperglycemia in patients with type2 diabetes mellitus(T2 DM). Methods A total of 300 patients with T2 DM who were admitted to our hospital from March 2016 to March 2019 were enrolled in the study. The selected patients were randomized and 150 patients receiving metformin monotherapy were included in group A, 150 patients. Patients who received both metformin and acarbose were included in group B. The postprandial hyperglycemia control and improvement of relevant clinical indicators were compared between the two groups. Results Before the treatment, the blood glucose index(FPG and 2 h PG) and HbAlc detection values were P>0.05, which was not statistically significant.After treatment, the blood glucose index(FPG and 2 h PG) and HbAlc detection value of group B were compared with A. The group was significantly decreased, P<0.05, statistically significant. Blood lipids, BMI and insulin index records showed that P>0.05 compared with the pre-treatment data of group A and group B, no statistical significance; after treatment, the above data of group B were significantly improved compared with group A, P<0.05, there were statistics. Learning meaning. The total probability of abdominal reactions such as abdominal pain, bloating, and nausea during the two groups was P>0.05, which was not statistically significant. Conclusion The combination of metformin and acarbose in the treatment of patients with T2 DM has obvious benefits in controlling postprandial hyperglycemia, reducing the body weight of patients, regulating blood lipids and insulin levels, and the two drugs are safe. Reliable and worth recommending.
引文
[1]Ma RC.Acarbose:an alternative to metformin for first-line treatment in type2 diabetes[J].Lancet Diabetes&Endocrinology,2014,2(1):6.
[2]Joshi SR,Ramachandran A,Chadha M,et al.Acarbose plus metformin fixeddose combination in the management of type 2 diabetes[J].Expert Opinion on Pharmacotherapy,2014,15(11):1611-1620.
[3]韩家凯,庞妩燕,杨秀真,等.二甲双胍联合阿卡波糖治疗2型糖尿病的疗效观察[J].中国卫生标准管理,2016,7(15):116-118.
[4]周建党.二甲双胍联合阿卡波糖治疗2型糖尿病疗效观察[J].吉林医学,2012,33(22):4797-4798.
[5]陈礼芳.阿卡波糖联合二甲双胍对2型糖尿病的疗效及安全性评价[J]临床医学工程,2014,21(12):1563-1564.
[6]魏巧.用阿卡波糖联合二甲双胍治疗2型糖尿病的疗效观察[J].当代医药论丛,2014,13(5):122-123.
[7]吴利.阿卡波糖或格列美脲联合二甲双胍对2型糖尿病患者餐后高血糖的疗效比较[J].湖南师范大学学报:医学版,2018,15(5):32-35.
[8]姚万丽.阿卡波糖联合二甲双胍治疗初发2型糖尿病伴高脂血症疗效观察[J].海峡药学,2018,30(5):47-49.
[9]Zhang JP,Wang N,Xing XY,et al.Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels[J].Journa of Diabetes,2016,8(4):559-567.
[10]许晓玲.阿卡波糖联合二甲双胍治疗初发2型糖尿病伴高脂血症的疗效观察[J].中国医药科学,2017,12(21):233-235.
[11]王丹,刘翠华.二甲双胍和阿卡波糖治疗2型糖尿病餐后高血糖的疗效观察[J].中国冶金工业医学杂志,2018,8(1):120-121.
[12]Ziaee A,Esmailzadehha N,Honardoost M.Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus[J].Pakistan Journal of Medical Sciences,2017,33(3):686-690.
[13]Sun W,Zeng C,Liao L,et al.Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obese[J].Current Medical Research&Opinion,2016,32(8):1.
[14]胡晓丽.阿卡波糖联合二甲双胍治疗新发肥胖2型糖尿病临床观察[J]中国医药科学,2015,13(22):159-161.
[15]王秀清.初发2型糖尿病伴高脂血症患者应用阿卡波糖联合二甲双胍治疗的疗效观察[J].实用妇科内分泌电子杂志,2015,2(6):172-173.
[2]Joshi SR,Ramachandran A,Chadha M,et al.Acarbose plus metformin fixeddose combination in the management of type 2 diabetes[J].Expert Opinion on Pharmacotherapy,2014,15(11):1611-1620.
[3]韩家凯,庞妩燕,杨秀真,等.二甲双胍联合阿卡波糖治疗2型糖尿病的疗效观察[J].中国卫生标准管理,2016,7(15):116-118.
[4]周建党.二甲双胍联合阿卡波糖治疗2型糖尿病疗效观察[J].吉林医学,2012,33(22):4797-4798.
[5]陈礼芳.阿卡波糖联合二甲双胍对2型糖尿病的疗效及安全性评价[J]临床医学工程,2014,21(12):1563-1564.
[6]魏巧.用阿卡波糖联合二甲双胍治疗2型糖尿病的疗效观察[J].当代医药论丛,2014,13(5):122-123.
[7]吴利.阿卡波糖或格列美脲联合二甲双胍对2型糖尿病患者餐后高血糖的疗效比较[J].湖南师范大学学报:医学版,2018,15(5):32-35.
[8]姚万丽.阿卡波糖联合二甲双胍治疗初发2型糖尿病伴高脂血症疗效观察[J].海峡药学,2018,30(5):47-49.
[9]Zhang JP,Wang N,Xing XY,et al.Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels[J].Journa of Diabetes,2016,8(4):559-567.
[10]许晓玲.阿卡波糖联合二甲双胍治疗初发2型糖尿病伴高脂血症的疗效观察[J].中国医药科学,2017,12(21):233-235.
[11]王丹,刘翠华.二甲双胍和阿卡波糖治疗2型糖尿病餐后高血糖的疗效观察[J].中国冶金工业医学杂志,2018,8(1):120-121.
[12]Ziaee A,Esmailzadehha N,Honardoost M.Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus[J].Pakistan Journal of Medical Sciences,2017,33(3):686-690.
[13]Sun W,Zeng C,Liao L,et al.Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obese[J].Current Medical Research&Opinion,2016,32(8):1.
[14]胡晓丽.阿卡波糖联合二甲双胍治疗新发肥胖2型糖尿病临床观察[J]中国医药科学,2015,13(22):159-161.
[15]王秀清.初发2型糖尿病伴高脂血症患者应用阿卡波糖联合二甲双胍治疗的疗效观察[J].实用妇科内分泌电子杂志,2015,2(6):172-173.